Zhengye Biotechnology Holding Limited (ZYBT)
NASDAQ: ZYBT · Real-Time Price · USD
10.06
+2.44 (32.02%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Company Description
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China.
It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt.
The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Zhengye Biotechnology Holding Limited
| Country | China |
| Founded | 2004 |
| IPO Date | Jan 7, 2025 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 286 |
| CEO | Songlin Song |
Contact Details
Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone Jilin, 132101 China | |
| Phone | 86 432 6304 7008 |
| Website | jlzybio.com |
Stock Details
| Ticker Symbol | ZYBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| IPO Price | $4.00 |
| CIK Code | 0001975641 |
| ISIN Number | KYG989MS1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aiden Han | Co-Chief Executive Officer |
| Songlin Song | Chief Executive Officer |
| Ping Wang | Chief Financial Officer |
| Zhongyao Liu | Chief Operating Officer |
| Yuhong Cheng | Vice General Manager |
| Wei Lian | Vice General Manager |
| Yuyou He | Vice General Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2025 | 6-K | Report of foreign issuer |
| Mar 6, 2025 | 6-K | Report of foreign issuer |
| Feb 21, 2025 | SCHEDULE 13G | Filing |
| Jan 14, 2025 | 6-K | Report of foreign issuer |
| Jan 8, 2025 | 6-K | Report of foreign issuer |
| Jan 7, 2025 | 424B4 | Prospectus |
| Jan 6, 2025 | CERT | Certification by an exchange approving securities for listing |
| Dec 20, 2024 | EFFECT | Notice of Effectiveness |
| Dec 19, 2024 | 8-A12B | Registration of securities |
| Dec 9, 2024 | POS AM | Post-Effective amendments for registration statement |